Oncostatin M and IL-6 induce u-PA and VEGF in prostate cancer cells and correlate in vivo.

BACKGROUND/AIM Oncostatin M (OSM) and interleukin-6 (IL-6) are growth factors for prostate cancer (PC). Vascular endothelial growth factor (VEGF) and urokinase-type plasminogen-activator (u-PA) have been implicated in tumour progression. A possible interaction between IL-6, OSM, u-PA and VEGF in PC was investigated. MATERIALS AND METHODS Primary prostate epithelial cells (PPEC) and DU-145 PC cells were treated with IL-6 or OSM and the effects on u-PA and VEGF expression were studied. Plasma levels of IL-6, OSM, u-PA and VEGF were determined in patients with or without PC. RESULTS In DU-145 cells, OSM and IL-6 up-regulated u-PA and VEGF significantly. Higher levels of IL-6 and OSM in metastasising PC than in nonmetastasising PC and benign prostatic hyperplasia (BPH) and correlations between IL-6, OSM, u-PA and VEGF were found. CONCLUSION OSM and IL-6 increase u-PA and VEGF in DU-145 cells but not in PPEC and possibly, by promoting matrix degradation and angiogenesis, could play a role in the pathogenesis of prostate cancer.

[1]  G. Maurer,et al.  Vascular Endothelial Growth Factor Is Induced by the Inflammatory Cytokines Interleukin-6 and Oncostatin M in Human Adipose Tissue In Vitro and in Murine Adipose Tissue In Vivo , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[2]  D. Fuchs,et al.  Interleukin‐6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen‐activated protein kinase and phosphatidylinositol 3‐kinase , 2005, The Prostate.

[3]  Georg Bartsch,et al.  Interleukin‐6 regulation of prostate cancer cell growth , 2005, Journal of cellular biochemistry.

[4]  G. Maurer,et al.  Inflammatory Cytokines Interleukin-6 and Oncostatin M Induce Plasminogen Activator Inhibitor-1 in Human Adipose Tissue , 2005, Circulation.

[5]  G. Bartsch,et al.  An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6. , 2004, European journal of cancer.

[6]  F. Blasi,et al.  The urokinase plasminogen activator system in cancer: Recent advances and implication for prognosis and therapy , 2003, Cancer and Metastasis Reviews.

[7]  L. Bégin,et al.  Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis , 2002, Molecular and Cellular Endocrinology.

[8]  D. Horsfall,et al.  A potential autocrine role for vascular endothelial growth factor in prostate cancer. , 2002, Cancer research.

[9]  P. Kantoff,et al.  Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  W. Folk,et al.  Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers. , 2001, European journal of cancer.

[11]  W. Li,et al.  Oncostatin M-Induced Matrix Metalloproteinase and Tissue Inhibitor of Metalloproteinase-3 Genes Expression in Chondrocytes Requires Janus Kinase/STAT Signaling Pathway1 , 2001, The Journal of Immunology.

[12]  G. Steiner,et al.  Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. , 2000, The Journal of urology.

[13]  S. Selman,et al.  Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients. , 2000, Oncology reports.

[14]  C. Fujiyama,et al.  Elevated serum vascular endothelial growth factor in patients with hormone‐escaped prostate cancer , 2000, BJU international.

[15]  P C Albertsen,et al.  Expression of vascular endothelial growth factor receptors in human prostate cancer. , 1999, Urology.

[16]  P. Kantoff,et al.  Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. , 1999, Urology.

[17]  J. Soria,et al.  Oncostatin M induces angiogenesis in vitro and in vivo. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[18]  H. Miyake,et al.  Elevation of serum levels of urokinase‐type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer , 1999, The Prostate.

[19]  B. Bonavida,et al.  Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor. , 1999, Anticancer research.

[20]  H. Miyake,et al.  Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. , 1999, International journal of oncology.

[21]  V. Laudone,et al.  Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. , 1997, The Journal of urology.

[22]  W. Tilley,et al.  Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. , 1997, The Journal of urology.

[23]  R. Sadasivan,et al.  Urokinase-type plasminogen activator expression in human prostate carcinomas. , 1996, The American journal of the medical sciences.

[24]  W Blumenfeld,et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.

[25]  J. Reynolds,et al.  The Role of Plasmhogen Activators in the Regulation of Connective Tissue Metalloproteinases a , 1992 .

[26]  D. Hart,et al.  Human HuH-7 hepatoma cells express urokinase and plasminogen activator inhibitor-1: identification, characterization and regulation by inflammatory mediators. , 1992, Biochimica et biophysica acta.

[27]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[28]  L. Liotta,et al.  Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. , 1981, Cancer research.

[29]  G. Ciliberto,et al.  Blocking signaling through the gp130 receptor chain by interleukin‐6 and oncostatin M inhibits PC‐3 cell growth and sensitizes the tumor cells to etoposide and cisplatin‐mediated cytotoxicity , 1999, Cancer.

[30]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[31]  M. Kattan,et al.  Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. , 1999, The Journal of urology.

[32]  R. Oyasu,et al.  Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. , 1997, Cancer research.

[33]  J. Folkman,et al.  Control of angiogenesis by heparin and other sulfated polysaccharides. , 1992, Advances in experimental medicine and biology.

[34]  B. Binder,et al.  Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors. , 1985, Invasion & metastasis.